Septerna Inc Reports Q3 2026 Results: Revenue of $18. ...
Clinical-Stage GPCR Developer Ends Quarter with $565.2 Million in Cash, Guidance to Fund Operations into mid-2029 Related Stocks: SEPN ,
Clinical-Stage GPCR Developer Ends Quarter with $565.2 Million in Cash, Guidance to Fund Operations into mid-2029 Related Stocks: SEPN ,